Peficitinib Explained
| Tradename: | Smyraf |
| Atc Prefix: | L04 |
| Atc Suffix: | AF06 |
| Legal Status: | Rx-only |
| Cas Number: | 944118-01-8 |
| Pubchem: | 57928403 |
| Unii: | HPH1166CKX |
| Kegg: | D10721 |
| Synonyms: | ASP015K; JNJ-54781532 |
| C: | 18 |
| H: | 22 |
| N: | 4 |
| O: | 2 |
| Smiles: | NC(=O)c1cnc2[nH]ccc2c1NC1[C@H]2CC3C[C@@H]1CC(O)(C3)C2 |
| Stdinchi: | 1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,1 |
| Stdinchikey: | DREIJXJRTLTGJC-JQCLMNFQSA-N |
Peficitinib (brand name Smyraf) is a pharmaceutical drug used for the treatment of rheumatoid arthritis. It belongs to the class of drugs known as Janus kinase inhibitors (JAK inhibitors).[1] [2]
Peficitinib was approved for use in Japan in 2019.[3]
Notes and References
- Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, Wang X, Garg JP, Zubrzycka-Sienkiewicz A . Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate . Arthritis & Rheumatology . 69 . 4 . 709–719 . April 2017 . 27748083 . 10.1002/art.39955 . free .
- Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, Shay K, Wang X, Garg JP, Cardiel MH . Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis . Arthritis & Rheumatology . 69 . 5 . 932–942 . May 2017 . 28118538 . 10.1002/art.40054 . free .
- Markham A, Keam SJ . Peficitinib: First Global Approval . Drugs . 79 . 8 . 887–891 . June 2019 . 31093950 . 10.1007/s40265-019-01131-y . 155093525 .
